IBD

Fifth Annual Broadridge Survey Reveals Time and Expertise Top Challenges in Advisor Marketing Strategies

Retrieved on: 
Wednesday, February 7, 2024
IBD, Broadridge Financial Solutions, RIA, Research, AI, Map, Millennials, Region, Marketing, Investment, Generation Z, Social media, Gen, Education, Financial adviser

NEW YORK and TORONTO, Feb. 7, 2024 /PRNewswire/ -- As macroeconomic volatility has led to an influx of investors seeking financial advice, advisors are increasingly looking to next-generation technology such as generative AI to address their marketing challenges and meet the increased personalization expectations of prospects and clients, according to global Fintech leader Broadridge Financial Solutions, Inc. (NYSE: BR) annual financial advisor marketing survey.

Key Points: 
  • In its fifth year, this annual survey evaluates North American registered financial advisors' sentiment and activities around digital marketing strategies, shedding light on the successes and challenges that advisors are facing.
  • The survey found that over half (56%) of Canadian advisors are currently using or plan to use generative AI in digital marketing strategies compared to 43% of U.S. advisors.
  • The number of advisors leveraging a defined marketing strategy has fallen due to the number of challenges that advisors face when it comes to marketing.
  • The top two challenges North American advisors face include finding time for marketing initiatives and sourcing the right expertise.

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Retrieved on: 
Monday, February 5, 2024
IBD, Senior, Inflammatory bowel disease, Patient, Bausch Health, Marketing, Antibody, Doctor of Philosophy, MBA, TL1A, Azusa Pacific University, SYRE, Bausch & Lomb, Therapy, Medicine, Prometheus, Merck, Merck & Co., University, Salix Pharmaceuticals, Arizona State University, Engineering, Pharmaceutical industry

Mr. McKenna's track record of corporate leadership, product development, and value creation, particularly in IBD.

Key Points: 
  • Mr. McKenna's track record of corporate leadership, product development, and value creation, particularly in IBD.
  • The Company looks forward to his guidance as it advances its potentially best-in-class antibodies targeting α4β7 and TL1A into clinical trials this year.
  • "Spyre had an impressive 2023, raising $390M through the capital markets with a syndicate of top-tier biotechnology investors," said Mr. McKenna.
  • In connection with Mr. McKenna's appointment to the Company's Board, Alison Lawton has resigned effective February 1, 2024.

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
Sunday, February 4, 2024
ALP, AGAF, IBD, Ascending cholangitis, Liver failure, Pharmacokinetics, SAN, Washington State University, Inflammation, Fibrosis, Cirrhosis, Itch, PSC, Ursodeoxycholic acid, MRI, Telephone, Magnetic resonance imaging, Inflammatory bowel disease, Patient, Safety, FDA, EMA, FACP, Disease, IPF, SAE, FRCP, ELF, Week, Therapy, Conference call, Alkaline phosphatase, Interest, UDCA, FACG, University, Webcast, Liver, Primary sclerosing cholangitis, Plasma, Liver disease, Conference, Medical imaging

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.

Key Points: 
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
  • INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily oral doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 121 patients with PSC.
  • The 320 mg group enrolled 27 patients in the active arm and added 9 new patients to the pooled placebo arm.

Boomerang Medical Awarded "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease" by the Crohn’s & Colitis Foundation

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, General Health, Health, Medical Devices, Health Technology, Philanthropy, Clinical Trials, Foundation, Multimedia, IBD, Research, Trial of the century, Ulcerative colitis, Inflammatory bowel disease, Medicine, Crohn's disease, Quality of life, Human, Movement, Pharmaceutical industry

Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.

Key Points: 
  • Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.
  • This award, given for the first time to a medical device company, acknowledges Boomerang Medical's alignment with the Foundation’s mission to improve the lives of those affected by inflammatory bowel disease.
  • The award was presented at the Foundation's annual President’s Corporate Circle reception, held during the annual Crohn’s & Colitis Congress® on January 26, 2024.
  • Heather Simonsen, CEO of Boomerang Medical, commented on the significance of this recognition: “We are deeply honored to be acknowledged by the Crohn’s & Colitis Foundation with this award.

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

Retrieved on: 
Tuesday, January 30, 2024
Patient, D. E. Shaw Research, Simulation, Atopic dermatitis, Membrane, UC, Lilly, DESRES, RNA, Robots in Disguise, PPI, IBD, AI, Microsoft Dynamics 365, Algorithm, DMPK, Eli Lilly and Company, Drug development, GPX4, Antibody, Prevalence, Intrinsically disordered proteins, Calcineurin, Eurosport 1, KCNA3, Internally displaced person, Conditional sentence, TH1, Drug discovery, Inflammatory bowel disease, Vaccine

The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.

Key Points: 
  • The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.
  • Inhibition of Kv1.3 therefore offers a potential opportunity to specifically impair inflammatory immune cell activity and proliferation, including in antigen-activated T cells.
  • Long-lived memory T-cell populations, particularly tissue resident subsets, may contribute to the chronicity of IBD and represent a potential target for therapy[4].
  • It has shown positive results in preclinical animal models of various autoimmune diseases such as IBD and AD.

EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

Retrieved on: 
Tuesday, January 30, 2024
Patient, IBD, Gastrointestinal disease, Euronext Paris, IND, Safety, Ulcerative colitis, IPO, Congress, FDA, A12, Therapy, Colitis, Pharmaceutical industry

Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.

Key Points: 
  • Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.
  • No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod.
  • Obefazimod follow-on candidate selection from miR-124 library: R&D work on potential follow-on drug candidates to be selected from Abivax’s compound library is ongoing.
  • Selection of the first follow-on drug candidate is expected in Q3 2024 to further strengthen the Abivax pipeline.

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

Retrieved on: 
Monday, January 29, 2024
Patient, Research, DSS, UC, Inflammatory bowel disease, DAI, Poster, PDE4, IBD, Dog, PDE4B, Plasma, AUC, Ulcerative colitis, Toxicity, Efficacy, Therapy, Vomiting, Absorption, Asian literature, Trial of the century, CNS, Pharmaceutical industry

Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn’s & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV.

Key Points: 
  • The preclinical data was presented in a poster titled, Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment.
  • PALI-2108 is the Company’s orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by moderate-to-severely active ulcerative colitis (UC).
  • The poster is available on the Scientific Publications page of the Company’s website .
  • This feature ensures localized bioactivation, leading to colon-specific distribution with limited systemic exposure, as confirmed by a tissue distribution study.

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Retrieved on: 
Thursday, January 25, 2024
Probability, Biology, Fibrosis, Organovo, SAN, Tissue, IBD, Inflammatory bowel disease, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Pharmaceutical industry

FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD.

Key Points: 
  • FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD.
  • FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn’s disease donors.
  • In ulcerative colitis, FXR314 improved epithelial barrier function and fibrotic activity in all donors.
  • Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 2024, with targeted completion in 2025.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

Retrieved on: 
Monday, January 22, 2024
Patient, IBD, Gastrointestinal disease, Euronext Paris, IND, Safety, Ulcerative colitis, IPO, Congress, FDA, A12, Therapy, Colitis, Pharmaceutical industry

Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.

Key Points: 
  • Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.
  • Recruitment into both induction trials, ABTECT-1 and ABTECT-2, is ongoing in all designated regions.
  • No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod.
  • Selection of the first follow-on drug candidate is expected in Q3 2024 to further strengthen the Abivax pipeline.